Clinical Trial Update: Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy and safety of Raphamin for acute respiratory viral infection in children aged 3-12, and the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Viral Infection

Drugs mentioned

• Raphamin (Raphamin)

Snippet

Sponsor: Materia Medica Holding | Conditions: Acute Respiratory Viral Infection | Phase 3 | Status: RECRUITING